April 19, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, is pleased to announce that the 12% Convertible Unsecured Subordinated Debentures (the “Debentures“) issued pursuant to the $15.0 million bought deal private placement closed on December 9, 2021, have been approved for listing on the TSX under the symbol “VPH.DB” and will begin trading on Tuesday April 19, 2022.
The Debentures have a maturity date of December 31, 2024 (the “Maturity Date“), and accrue interest at the rate of 12% per annum payable quartertly. At the holders’ option, the Debentures may be converted into Class A shares of the Company at any time and from time to time, up to the Maturity Date, at a conversion price of $1.15 per Class A share.
For additional details regarding the Debentures, please refer to the Debenture Indenture dated December 9, 2021, which is available at www.SEDAR.com.
Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
This press release contains forward-looking statements about Valeo Pharmas’s objectives, strategies and businesses that involve risks and uncertainties, including statements about the Offering, the Concurrent Private Placement and the anticipated use of proceeds therefrom. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
SOURCE Valeo Pharma Inc.
For further information: Steve Saviuk, CEO, 514-693-8830, [email protected] or Luc Mainville, Senior Vice-President and Chief Financial Officer, 514-693-8854, [email protected] or Frederic Dumais, Director, Communications and Investor Relations, 514-782-8803, [email protected]
